Central Serous Chorioretinopathy

Overview & Epidemiology

Central serous chorioretinopathy (CSCR, sometimes shortened to CSC) is a macular disease of the choroid, not the retina. A congested, leaky choroidal circulation overwhelms the retinal pigment epithelium's capacity to keep the subretinal space dry, and fluid accumulates beneath the neurosensory retina. The demographic skew is one of the sharpest in ophthalmology: middle-aged men, typically in their thirties to fifties, with a male-to-female ratio reported anywhere from roughly 6:1 to 10:1. Peak incidence falls in the fourth decade of life, and the classic patient also carries a competitive, high-stress "type A" behavioral profile.

Most cases are self-limited. The fluid resorbs over weeks to a few months, and vision recovers fully. A meaningful subset become chronic or recurrent instead, and it is this chronic form, not the typical acute episode, that causes lasting RPE damage and permanent vision loss if left untreated.

Pathophysiology

The current model centers on choroidal vascular hyperpermeability with secondary RPE dysfunction. Congested, leaky choroidal vessels raise hydrostatic pressure in the choroid, overwhelming the RPE's ion-pump and tight-junction barrier function. Once that outer blood-retinal barrier breaks down, serous fluid crosses from the choroid into the subretinal space faster than the RPE can pump it back out.

CSCR is now understood as part of the pachychoroid disease spectrum. "Pachychoroid" describes an abnormally thick choroid with attenuation of the choriocapillaris and dilated outer choroidal (Haller's layer) vessels. This same structural substrate underlies several related pachychoroid entities, including pachychoroid pigment epitheliopathy and pachychoroid neovasculopathy, with CSCR representing the form that produces overt subretinal fluid.

Risk Factors

Corticosteroids, in any form, systemic, topical, inhaled, or intra-articular, are the single most well-established exogenous trigger. They are thought to act by increasing choroidal vascular permeability and impairing RPE function. The same logic extends to endogenous cortisol excess: Cushing syndrome, whether from an endogenous source or exogenous steroid use, is a recognized association for the same reason.

Beyond steroids, CSCR has been linked to monoamine oxidase inhibitors, through effects on catecholamines and vascular tone, obstructive sleep apnea, via intermittent hypoxia with sympathetic activation and cortisol surges, and psychosocial stress consistent with the classic type A profile. On the genetics side, polymorphisms in complement factor H, the same gene implicated in age-related macular degeneration, have been associated with CSCR susceptibility. This points to a shared complement-mediated component across choroidal disease more broadly.

Clinical Presentation

Patients typically report metamorphopsia and a relative central scotoma, sometimes with micropsia, objects appearing smaller, reflecting a localized serous detachment of the neurosensory retina at the macula. The process is subacute and painless: not the sudden total vision loss of a vascular occlusion, and not the peripheral field loss of a retinal detachment.

Imaging

OCT is the primary diagnostic tool. It typically shows a dome-shaped shallow serous elevation of the neurosensory retina with optically clear, hyporeflective subretinal fluid, often overlying a focal pigment epithelial detachment that corresponds to the underlying leak point.

Fluorescein angiography localizes the leak. The classic pattern, a "smokestack" in which dye escapes from a focal RPE defect and rises vertically before mushrooming outward, is actually the less common one, seen in only about 10 to 15% of acute cases. A slower expanding inkblot pattern is far more typical.

Indocyanine green angiography is the modality that best demonstrates the underlying choroidal problem itself. It shows multifocal areas of choroidal vascular hyperpermeability and dilated choroidal vessels, confirming the pachychoroid substrate and most useful in atypical or chronic presentations.

Chronic Disease

In long-standing chronic CSCR, subretinal fluid that persists or recurs over months migrates under gravity, producing descending strips of RPE atrophy known as gravitational tracks. Their presence marks more significant, cumulative RPE decompensation, not a fresh, self-limited episode.

Chronic disease also raises the risk of a secondary choroidal neovascular membrane, found on angiography in roughly one in five long-standing cases. New metamorphopsia or a sudden drop in vision in a patient with known chronic CSCR warrants a look for this complication rather than an assumption that it is just another flare. Confirmed CNV is managed with the same anti-VEGF therapy used for wet AMD.

Treatment

Because most acute episodes resolve spontaneously, observation is often reasonable first-line management. Left untreated, though, recurrence is common: up to half of patients who are simply observed go on to have another episode. For chronic or recurrent disease with persistent leakage, half-dose (half-fluence) photodynamic therapy with verteporfin is preferred. It reduces choroidal vascular hyperpermeability while limiting collateral damage to the RPE and choriocapillaris compared to full-dose PDT. When angiography instead shows a single leak point well away from the fovea, thermal focal laser photocoagulation to seal it is a reasonable alternative that speeds fluid resolution, though it carries a small risk of inducing a new neovascular membrane at the treatment site and, unlike PDT, does not lower the recurrence rate. Anti-VEGF therapy and vitrectomy are not first-line: CSCR is not primarily a neovascular or vitreoretinal traction disease. And given the steroid association, escalating oral corticosteroids for an unrelated indication in a CSCR patient can actively worsen it.

High-Yield Pearls

• CFH gene polymorphisms link CSCR to the same complement pathway implicated in AMD.
• ICGA, not OCT or FA, is the best test for demonstrating the underlying choroidal vascular hyperpermeability.
• Corticosteroids can trigger CSCR and are also the wrong treatment to reach for if CSCR is misdiagnosed as something inflammatory.

Related Topics

Continue exploring Retina & Vitreous: